Key Highlights

  • Fourth-quarter Revenue was USD 1.30 billion, against USD 1.32 billion.
  • Adjusted EPS was USD 2.11, against a USD 1.85 estimate.
  • Operating income rose to USD 157.4 million from USD 122.9 million.
  • Full-year adjusted EPS reached USD 8.24, up 12.0%.

Profit beat expectations at Maximus (NYSE:MMS) even though revenue dipped. Fiscal fourth-quarter 2026 revenue was USD 1,300,808 thousand versus USD 1,318,415 thousand, in line with an estimate of USD 1.30 billion. Adjusted diluted EPS was USD 2.11 versus USD 1.62 a year earlier and an estimate of USD 1.85, while GAAP diluted EPS was USD 1.83 versus USD 1.32. Operating Income was USD 157,416 thousand versus USD 122,862 thousand, and Net Income was USD 97,005 thousand versus USD 75,288 thousand.

The company completed its Acquisition of Agile Defense on November 18, 2026. The chief executive tied the year's results to technology-enabled productivity enhancements and Capital allocation.

Segments and the Full Year

U.S. Federal Services revenue was USD 731,283 thousand at a 19.8% segment margin, compared with USD 747,935 thousand and 15.1%. U.S. Services revenue rose to USD 432,325 thousand from USD 429,273 thousand at a 9.2% margin, and Outside the U.S. revenue was USD 137,200 thousand with a small segment loss. The quarter reflected a customer-directed change to performance incentives on the VA Medical Disability Examination program.

Fiscal 2026 revenue was USD 5.23 billion versus USD 5.43 billion, which the company says had benefited from elevated disaster support and clinical Volume surges. Operating Margin was 11.7% versus 9.7%, and adjusted EBITDA margin was 14.2% versus 12.9%. Diluted EPS was USD 7.27, and adjusted diluted EPS was USD 8.24 versus USD 7.36. Fiscal 2026 included about USD 75 million of VA incentive revenue and USD 1.05 of adjusted EPS.

Cash, Awards and Returns

Cash was USD 280 million and gross Debt was USD 1.61 billion at September 30. Full-year Operating Cash Flow was USD 112 million and free cash flow was USD 69 million, with USD 278 million of free cash flow in the fourth quarter. The company collected more than USD 330 million from a major customer after year-end, and Days Sales Outstanding were 93 versus 98 at June 30.

Signed awards were USD 2.51 billion for the year, with USD 1.86 billion pending and a fourth-quarter book-to-bill ratio of about 1.0x. The quarter included a state Medicaid renewal worth more than USD 800 million over ten years. The sales pipeline was USD 44.8 billion and the recompete win rate was about 89%. The company repurchased about 2.6 million shares for roughly USD 192 million and declared a USD 0.33 quarterly dividend.

Guidance for Fiscal 2027

The company guides fiscal 2027 revenue of USD 5.45 billion to USD 5.65 billion, adjusted diluted EPS of USD 7.50 to USD 8.00, free cash flow of USD 700 million to USD 800 million and an adjusted EBITDA margin of about 12.8%. The outlook includes about ten months of Agile Defense revenue and assumes no VA incentive contribution.

After the acquisition, pro forma Leverage is guided at about 2.3x, inside the 2x to 3x target range. Agile Defense integration, the cash collections that moved into fiscal 2027 and state Medicaid program activity are the points to follow.